Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 100 Million+ Visitors
  • 75000+ Unique visitors per conference
  • 100000+ Page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

BIOMARKERS CONGRESS-2020

About Conference


Dear Potential Researchers, Scientists, Industrialists & Students,

Join us for 2nd International Conference on Biomarkers and Clinical Research

Update your skills, Meet your academic heroes, Engage in high-level debates and refine your ideas enhance your knowledge base, and broaden your horizons, Visit a new place and have fun, - all in one place!

Date: June 15-16, 2020

Venue: Dubai, UAE

If you are interested to be a part of this event as a speaker or delegate!

Email: lucywatson@memeetings.net

Call: 1-201-380-5561 (Extension No- 7007)

WhatsApp: +44 7723584505


Biomarkers Conference 2020 provides a vital forum for the exchange of ideas and innovative concepts in all areas related to biomarkers. Biomarkers 2020 particularly welcome clinical trials and statistical studies as well as methodologically sound literature reviews.The conference program is based on a wide range of challenges and issues in the field of biomarkers that will be addressed through plenary speakers, keynote speakers, eminent professors and medical professionals, along with poster sessions.

We are looking forward to an inspiring two-day research event, business meeting, trade show and exhibition in Dubai, UAE.

Why to Attend Biomarkers Conference 2020?

  • Categorizing innovations based on research and practice to optimize clinical research and development of biomarkers.
  • To promote opportunities to network, collaborate and exchange ideas with world-renowned Biomarkers research leaders.
  • Recognizing opportunities for evidence-based training to improve research and development of Biomarkers.
  • To discuss and debate the challenges and prospects in the new era of optimizing reforms in clinical research and development.
  • Dispute discrepancies and sustainable development goals in improving research and development of Biomarkers.

Target Audience of Biomarkers Conference 2020

  • Clinical researchers
  • Cancer researchers
  • Radiologists
  • Oncologists
  • Cardiologists
  • Neurologists
  • Geneticists
  • Pathologists
  • Molecular biologists
  • Immunologists
  • Pharmacologists
  • Young researchers
  • Students
  • Biomarker associations
  • Biomedical industrials
  • Medical devices specialists
  • Business enterpreneurs
  • Diagnostic experts

Session/Tracks

TRACK 1: Biomarkers

Biomarkers are molecules that signify an irregular process in your body and may be a sign of underlying disease or illness. Various types of molecules, such as DNA (genes), proteins, or hormones, can be used as biomarkers because they all mean something about your health. In response to cancer, biomarkers can be produced by the cancer tissue itself or by other cells in the body. These can be found in blood, stool urine, tumor or other tissues or body fluids. Biomarkers, in particular, are not restricted to cancer. Biomarkers are available for cardiac disease, multiple sclerosis, and many other diseases.

TRACK 2: Biomarkers in Diagnosis

Biomarkers and diagnostics play a vital role in enhancing the quality of human health outcomes and findings in clinical settings. In both preclinical and clinical settings, translational biomarkers and diagnostics can be implemented. It should seek to turn the findings into medical practice and practical health outcomes in fundamental research. This session will discuss the characteristics of acceptable translational biomarkers and the different approaches to their selection, including the latest trends and developments in translational biomarkers and diagnostics.

TRACK 3: Biomarker Testing

The term "biomarker" refers to any of the molecules of your body that can be assessed for health assessment. Molecules can be extracted from your blood, body fluids, or tissue. Biomarker screening is a collection of tests that searches for these molecular indicators of health so physicians can prepare the best care. Often named "molecular testing" or "genetic testing" may be biomarker testing.

Many cancer biomarkers are used to determine the likelihood of a person developing cancer. For early detection (screening) and identification (diagnosis) of cancer, other cancer biomarkers are used. Biomarkers can be used to plan the best treatment after a diagnosis of cancer. If not on treatment, biomarkers may also be used to track outcomes of treatment or cancer growth. Biomarker assessments can be subdivided into three groups.

TRACK 4: Clinical Biomarkers

Biomarkers used for clinical purposes are referred to as clinical biomarkers. Clinical biomarkers are an important and powerful way to understand the nature of many diseases and epidemiology, random clinical trials, drug screening, or diagnosis and prognosis of disease. It is defined as changes in cell or body fluid constituents, these clinical biomarkers offer the means for standardized classification of a disease and risk factors that can extend the basic information on the underlying pathogenesis of diseases.

The major medical biomarker research is conducted in the fields of drug discovery, pharmacogenomics, oncology, and diagnosis of disease. Biomarker categories in clinical trials are categorized into biomarkers for safety and efficacy.

TRACK 5: Digital Biomarkers

The spread of wearable digital technologies in the generation of big data in health care resulted in the appearance of a new type of medical information. We produce actionable insights into individuals ' biological environment, just as "normal" biomarkers, but are gathered by digital tools. Here is our summary of the significance of digital biomarkers and how they will be used in the near future.

X-ray or DNA test results are not part of the digital biomarker area.


TRACK 6: Neurological Biomarkers

Neurological biomarkers are present only at or imperceptibly in the blood in the CSF (cerebrospinal fluid).The blood-brain barrier effectively protects the brain from toxic chemicals entering into the bloodstream. Unfortunately this barricade has also made brain chemistry unachievable for proper blood testing for diagnostic purposes. CSF may be used to test neurological biomarkers, but this involves an invasive and painful technique of lumbar puncture.

TRACK 7:Biomarkers in Oncology

Biomarkers play a significant role in oncology used for risk assessment, differential diagnosis, evaluating the type of tumors, determining the prognosis and dose-response of the medication to treatment for detection purposes. The mechanism that indicates the presence of cancer in the body is conducted using instruments known as cancer biomarkers. Biomarkers have their application in various types of cancer, such as lung, melanoma, breast, colorectal, pancreas, and many more. Biochemically, biomarkers of cancer may include DNA, RNA, proteins, peptides, hormones, metabolites, and biological processes such as apoptosis, angiogenesis, or proliferation. Based on their medical use, there are three main types of cancer biomarkers: Prognostic, Predictive, pharmacodynamic markers.

TRACK 8: Biomarkers in Non Cancerous Diseases

Biomarkers play a vital role in the prognosis and diagnosis of various cardiovascular and neurological diseases. Diseases that are deadly from ancient times can be treated and easily diagnosed using advances in biomarkers through different methods of diagnosis and imaging. In the diagnosis and prognosis of disease, cardiac biomarkers and neurobiomarkers brought a great revolution. In many other non-cancerous diseases, these biomarkers are also used. 

TRACK 9: Cardiac Biomarkers

Cardiovascular markers are biomarkers assessed to test cardiac function. They are often discussed in the context of myocardial infarction, but other conditions may result in an elevation of the heart marker level. When the heart is damaged or strained, Cardiac biomarkers are the elements that are released to the blood. A cardiac marker is used in patients with chest pain and suspected acute coronary syndrome (ACS) identification and risk stratification. Such markers include genes, proteins and hormones. Over the past 50 years, cardiac biomarkers have evolved as essential tools in cardiology, i.e. primary and secondary prevention, diagnosis and treatment of acute myocardial infarction (AMI), and the diagnosis and stratification of heart failure risk.

TRACK 10: Immunological Biomarkers

Biomarkers that can control different immune system diseases such as autoimmunity, immunodeficiency, cancer, allergies, and infections are considered immunological biomarkers. This plays a very important role in the identification of biomarkers as the immune system interacts with all the other processes in the body. Immunological biomarkers including miRNA and serum biomarkers can provide data about a body's immune response under normal or unusual conditions.

TRACK 11: Genomic Biomarkers

Genomic biomarkers are variations in the DNA code that are correlated with susceptibility to infection, disease expression and disease outcome, including therapeutic responses. Single nucleotide polymorphisms (SNPs; change in the DNA code when a single nucleotide is changed in the genome sequence) have been thoroughly studied in relation to CVD. The two classic complementary methods used to link genetic sequence variability to CVD risk are the linkage technique and the strategy of association. The primary objective of the Human Genome Project was to identify and develop such biomarkers for "personalized, preventive and predictive medicine."

TRACK 12:Biomarkers for bipolar disorders

Biomarkers research in bipolar disorder is a new field with an expanding knowledge. It is associated with imbalances in various biological systems, including the immune system, neurotrophins, neuroendocrine axis, and oxidative stress. External molecules related to the pathophysiological mechanisms underlying the bipolar disorder may be a potential biomarker of the disease. Bipolar disorder is correlated with structural and functional changes in neuroimaging consistent with brain atrophy, including expansion of lateral ventricles and loss of prefrontal cortex and amygdala volumes. Bipolar disorder peripheral and neuroimaging findings may reflect neuroprogressive disease processes. It seems unlikely that a single candidate biomarker will tap the clinical and biological heterogeneity of bipolar disorder.

TRACK 13: Biomarkers in Pharmacology

Pharmacological research plays a crucial role in the development of cancer drugs. In especially in recent years, biomarker research studies has become an integral part of this process, specifically the use of pharmacological biomarkers in the development of targeted therapies and their translation into clinical practice. Clinical pharmacology is the science of drugs in human disease prevention, treatment, and control. A comprehensive understanding of clinical pharmacology principles is essential for any clinician to deliver optimal therapy to individual patients.

TRACK 14: Biomarkers in Drugs

Biomarkers have a tremendous potential to affect clinical trial success rate and identify new drug targets and advance diagnostic assays for early disease detection. The development of biomarkers originates in the phase of drug discovery and leads to clinical validation. In the target, biomarkers are used in the discovery and validation stage to identify and justify therapy targets. Biomarkers should have accurate qualities with an acceptable sensitivity and specificity representing a particular drug toxicity or therapeutic effect, a specific physiological response to a therapy, a pathological progression, or a physiological factor.

TRACK 15: Clinical Research

Clinical research refers to all human (healthy or sick) research. It focuses on improving the knowledge of diseases, developing diagnostic and new treatments or medical devices to ensure better patient care. Clinical research is a branch of social security science that evaluates the well-being and efficacy of the approaches, tools, experimental components, and treatment regimes intended for human use.

By using prognostic biomarker, different types of reporting bias and publishing bias make the connection between CRP and prognosis among patients with stable coronary artery disease one of the most emerging innovative projects. Publication bias, statistical analytical protocols and study registration are one of the other measures that could help to improve the quality of biomarker research.

TRACK 16: Proteomics and Genomics

The identification and development of biomarkers for personalized, preventive and predictive medicine was a key thrust of the Human Genome Project. Genomics-related biomarkers test changes in the volume or composition of nucleic acids. Biomarkers dependent on DNA include differences in the number of copies, mutations (including polymorphisms, somatic mutations and other genetic variants) and epigenetic modifications. RNA expression-based biomarkers include quantification of mRNA, microRNA, and long non-coding RNA expression. Proteomics was widely used to study a wide range of medical fields including the development of drugs and the discovery of biomarkers.

TRACK 17: Clinical Trail Supply Management

In-house, clinical preliminary treatment can now and again be an organisational and functional weight. By outsourcing clinical preliminary dispersion halfway, pharmaceutical research associations will often have the ability to free up internal assets and, meanwhile, improve the safety and nature of their preliminary drug transmission.

TRACK 18: Biomarkers-Validation and Verification

The discovery of biomarkers requires highly confident identification of candidates for biomarkers with simultaneous quantitation information to indicate which proteins are changing in response to disease to a statistically relevant level. Because of natural medical or biological variability, a large number of samples need confirmation of candidate biomarkers identified in the discovery phase. The challenge is to develop a fast, targeted analysis method capable of analysing as many identified candidates as possible in minimally hundreds and potentially even thousands of samples.

TRACK 19: Emerging Therapeutic Biomarkers

A reliable therapeutic biomarker would enable the identification of current management algorithms, ensure the elimination of pathogenic mechanisms prior to withdrawal from treatment, and reduce the frequency of unnecessary sustained therapy. As a result, various studies are underway to discover new biomarkers for various diseases, from cardiovascular disorders to autoimmune disorders and genetic disorders.

TRACK 20: Advancements in Biomarkers

Biomarker use and analytical tests continue to develop with more implementations and much more efficient sensitivity assays being introduced. These tests are powerful clinical tools that approach different therapeutic areas. Recent developments in biosensors to detect biomarkers in the treatment of cancer.

 

Market Analysis

Global Market Analysis of Biomarkers and Clinical Research Conference

In 2018, the global market for biomarkers stood at USD 41.2 billion and is expected to generate around USD 108.4 billion by 2025, with a CAGR of around 14.8% between 2019 and 2025.

According to industrial, academical and reseachers statistics university reseachers takes the first position with 32%, government research takes the second position with 24%, where research and development takes third position with 18% and diagnostic laboratories, medical research facilities takes fourth and fifth places with 14% and 12% respectively.

The global market for cancer biomarker is segmented based on the type, application and disease of biomarkers. Based on the type of biomarker, the biomarker market is classified into security, validation, and efficacy biomarkers. Due to the increasing product adoption in drug discovery and development, safety biomarkers accounted for the highest market share in 2018. In addition, they are used in preclinical research trials to identify drug candidates that are likely to be well-tolerated by people, which helps to reduce drug development and preclinical safety costs and time.

The biomarkers market based on application, includes personalized medicine, diagnosis, discovery and development of drugs, and others. In 2018, drug discovery and development accounted for a significant market share.

Biomarkers affect the decision of the major market players as to whether the later phases of clinical development will proceed. In addition, a growing number of R&D initiatives are undertaken by pharmaceutical giants to develop targeted therapies.

BIOMARKERS MARKET IS ESTIMATED TO BE VALUED AT USD 78.2 BILLION BY 2024

By disease, the biomarkers market comprises immunological diseases, cancer, neurological diseases, cardiovascular diseases, and others. The cancer segment dominates the global biomarkers market, due to the growing demand for accurate and rapid diagnostic tools and rising cancer incidences globally. According to the National Cancer Institute, about 268,670 new cases of breast cancer were recorded in 2018 in the U.S.

Throughout 2018, North America dominated the biomarkers worldwide market and is also likely to remain dominant over the forecast period. This regional dominance can be attributed to the regional presence of major pharmaceutical and biotechnology firms, increased adoption of the latest technologies and  established  healthcare infrastructure

The U.S. is North America's leading market for biomarkers, which is expected to record the highest CAGR in the coming years. This regional market will also be boosted by government funding for research activities. In 2016, about 16.8 million new cases of cancer were reported in the world, and 5.95,690 deaths were caused by cancer, according to the National Cancer Institute. In addition, government cooperation with several research institutes to develop cancer research and other chronic diseases for the purpose of diagnosis and treatment would fuel this market further.

In the upcoming years, the Asia Pacific region is expected to record high growth in the global biomarker industry.The rising incidence of chronic diseases such as neurological disorders, cancer and cardiovascular diseases, increased regional government support for drug discovery and development programs, increased awareness of disease diagnosis among biomarkers and a large pool of patients are the main factors that boost the development of the biomarkers market.

In the upcoming years, the Asia Pacific region is expected to record high growth in the global biomarker industry.The rising incidence of chronic diseases such as neurological disorders, cancer and cardiovascular diseases, increased regional government support for drug discovery and development programs, increased awareness of disease diagnosis among biomarkers and a large pool of patients are the main factors that boost the development of the biomarkers market in the asia pacific.

    WORLD BIOMARKERS MARKET:MARKET SHARES (%) BY COUNTRIES

China, Japan, and India are expected to be major contributors to the Asia Pacific biomarkers market in the future. The favorable environment for clinical trials in the Asia Pacific is likely to fuel the biomarkers market over the forecast period.

Scope and Importance

In the subsections of representative diseases, the biomarker market presents the highest of all prospects. This study looks at one of the market's most important engines: Overview of the combination analyses, which are estimated to continue to make a significant contribution to market innovations during the forecast period. This report analyzes emerging markets in the disease segment. Endless growth is estimated in emerging geographies, driven by the growing middle class in emerging countries like India, China, Brazil, and Russia. It is important to stress that the ability to integrate an effective strategy begins with the place where the opportunity exists and ends with the way in which it can be effectively implemented in order to reap the benefits of the opportunity.

Why Biomarkers Conference 2020 in Dubai?

Biomarkers Conference 2020 will be held in Dubai. Dubai is a global city and a business(commercial) hub for the Middle East. It is also a major global transport hub for passengers and cargo. Oil revenues helped increase the development of the city, which was already a major commercial hub. Today, less than 5% of the Emirate's revenue comes from oil. As a center for regional and international trade since the early twentieth century, Dubai's economy relies on revenues from trade, tourism, aviation, real estate and financial services. Dubai is definitely a 21st century destination, any article about the fastest growing city in the region and it's almost guaranteed you'll see the words‘ ambitious',‘ record-breaking’ and‘ staggering'. This meteoric rise has not gone unnoticed, and each year thousands of expats arrive to demand a slice of the action.

Past Conference Report

Biomarkers Congress-2019

Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date June 15-16, 2020

For Sponsors & Exhibitors

sponsor@conferenceseries.com

Speaker Opportunity

Supported By

Journal of Molecular Biomarkers & Diagnosis Biomarkers Journal Journal of Cancer Science & Therapy Journal of Molecular and Genetic Medicine

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by